Your institution may have access to this item. Find your institution then sign in to continue.
Title
Tolvaptan.
Authors
Ghali, Jalal K; Hamad, Bashar; Yasothan, Uma; Kirkpatrick, Peter
Abstract
In May 2009, tolvaptan (Samsca; Otsuka), a selective vasopressin V(2) receptor antagonist, was approved by the US FDA for the treatment of clinically significant hypervolaemic and euvolaemic hyponatraemia.
Publication
Nature reviews. Drug discovery, 2009, Vol 8, Issue 8, p611